ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 4,500 shares, a drop of 65.9% from the March 31st total of 13,200 shares. Based on an average trading volume of 17,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

ImmuCell Price Performance

Shares of NASDAQ:ICCC opened at $5.50 on Friday. The company has a market capitalization of $49.41 million, a PE ratio of -11.00 and a beta of 0.39. The company’s fifty day moving average is $5.13 and its 200-day moving average is $4.71. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11. ImmuCell has a 52 week low of $3.34 and a 52 week high of $5.82.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The business had revenue of $7.75 million for the quarter.

Institutional Trading of ImmuCell

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dauntless Investment Group LLC acquired a new position in shares of ImmuCell in the 4th quarter valued at $676,000. Geode Capital Management LLC lifted its position in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after buying an additional 7,878 shares in the last quarter. Northern Trust Corp boosted its position in ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 14,982 shares during the last quarter. Citadel Advisors LLC acquired a new stake in ImmuCell in the fourth quarter valued at $149,000. Finally, Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the period. 13.47% of the stock is owned by institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.